Abstract
Huntington’s disease (HD) is a monogenic, autosomal dominant inherited fatal disease that affects 1 in 10,000 people worldwide. Given its unique genetic characteristics, HD would appear as one of the most straightforward neurodegenerative diseases to replicate in animal models. Indeed, mutations in the HTT gene have been used to generate a variety of animal models that display differential pathologies and have significantly increased our understanding of the pathological mechanisms of HD. However, decades of efforts have also shown the complexity of recapitulating the human condition in other species. Here we describe the three different types of models that have been generated in nonhuman primate species, stating their advantages and limitations and attempt to give a critical perspective of their translational value to test the efficacy of novel therapeutic strategies. Obtaining construct, phenotypic, and predictive validity has proven to be challenging in most animal models of human diseases. In HD in particular, it is hard to assess the predictive validity of a new therapeutic strategy when no effective “benchmark” treatment is available in the clinic. In this light, only phenotypic/face validity and construct validity are discussed.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Duyao M, Ambrose C, Myers R et al (1993) Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 4:387–392
The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983
Shao J, Welch WJ, Diprospero NA, Diamond MI (2008) Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 28:5196–5208
Tobin AJ, Signer ER (2000) Huntington’s disease: the challenge for cell biologists. Trends Cell Biol 10:531–536
Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci 6:919–930
Vonsattel JP, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577
Ferrante RJ, Kowall NW, Beal MF et al (1985) Selective sparing of a class of striatal neurons in Huntington’s disease. Science 230(4725):561–563
Ferrante RJ, Beal MF, Kowall NW et al (1987) Sparing of acetylcholinesterase-containing striatal neurons in Huntington’s disease. Brain Res 411:162–166
Kowall NW, Quigley BJ Jr, Krause JE et al (1993) Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul Pept 46:174–185
Cicchetti F, Prensa L, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease. Brain Res Rev 34(1–2):80–101
Walker FO (2007) Huntington’s disease. Semin Neurol 27(2):143–150
Lawrence AD, Sahakian BJ, Hodges JR et al (1996) Executive and mnemonic functions in early Huntington’s disease. Brain 119:1633–1645
Cummings JL (1995) Behavioral and psychiatric symptoms associated with Huntington’s disease. Adv Neurol 65:179–186
Duff K, Paulsen JS, Beglinger LJ et al (2007) Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study. Biol Psychiatry 62:1341–1346
Marshall J, White K, Weaver M et al (2007) Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol 64:116–121
Huntington G (2003) On chorea. George Huntington, M.D. J Neuropsychiatry Clin Neurosci 15:109–112
Young AB, Shoulson I, Penney JB et al (1986) Huntington’s disease in Venezuela: neurologic features and functional decline. Neurology 36:244–249
Ramaswamy S, McBride JL, Kordower JH (2007) Animal models of Huntington’s disease. ILAR J 48:356–373
Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington’s disease. Nat Rev Neurosci 14:708–721
Hantraye P, Riche D, Maziere M, Isacson O (1990) A primate model of Huntington’s disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 108:91–104
Kanazawa I, Tanaka Y, Cho F (1986) ‘Choreic’ movement induced by unilateral kainate lesion of the striatum and L-DOPA administration in monkey. Neurosci Lett 71:241–246
Kanazawa I, Sasaki H, Muramoto O et al (1985) Studies on neurotransmitter markers and striatal neuronal cell density in Huntington’s disease and dentatorubropallidoluysian atrophy. J Neurol Sci 70:151–165
Ferrante RJ, Kowall NW, Cipolloni PB et al (1993) Excitotoxin lesions in primates as a model for Huntington’s disease: histopathologic and neurochemical characterization. Exp Neurol 119:46–71
Burns LH, Pakzaban P, Deacon TW et al (1995) Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 64:1007–1017
Roitberg BZ, Emborg ME, Sramek JG et al (2002) Behavioral and morphological comparison of two nonhuman primate models of Huntington’s disease. Neurosurgery 50:137–145. discussion 145–146
DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington’s disease. Trends Neurosci 13:286–289
Schumacher JM, Hantraye P, Brownell AL et al (1992) A primate model of Huntington’s disease: functional neural transplantation and CT-guided stereotactic procedures. Cell Transplant 1:313–322
Kendall AL, David F, Rayment G et al (2000) The influence of excitotoxic basal ganglia lesions on motor performance in the common marmoset. Brain 123:1442–1458
Brownell AL, Hantraye P, Wullner U et al (1994) PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. Exp Neurol 125:41–51
Schwarcz R, Tamminga CA, Kurlan R, Shoulson I (1988) Cerebrospinal fluid levels of quinolinic acid in Huntington’s disease and schizophrenia. Ann Neurol 24:580–582. https://doi.org/10.1002/ana.410240417
Campbell BM, Charych E, Lee AW, Moller T (2014) Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 8:12. https://doi.org/10.3389/fnins.2014.00012
Beal MF, Kowall NW, Ellison DW et al (1986) Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321(6066):168–171
Gardian G, Vecsei L (2004) Huntington’s disease: pathomechanism and therapeutic perspectives. J Neural Transm (Vienna) 111:1485–1494
Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington’s disease phenotype in experimental animals. Prog Neurobiol 59:427–468
Ludolph AC, He F, Spencer PS et al (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492–498
Palfi S, Ferrante RJ, Brouillet E et al (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington’s disease. J Neurosci 16:3019
Palfi S, Leventhal L, Goetz CG et al (2000) Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord 15:524–530
Brouillet E, Hantraye P (1995) Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr Opin Neurol 8:469–473
Brouillet E, Hantraye P, Ferrante RJ et al (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 92:7105–7109
Beal MF, Brouillet E, Jenkins BG et al (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181–4192
Dautry C, Conde F, Brouillet E et al (1999) Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis 6:259–268
Dautry C, Vaufrey F, Brouillet E et al (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20:789–799
Yang SH, Cheng PH, Banta H et al (2008) Towards a transgenic model of Huntington’s disease in a non-human primate. Nature 453:921–924
Chan AW, Xu Y, Jiang J et al (2014) A two years longitudinal study of a transgenic Huntington disease monkey. BMC Neurosci 15:36. https://doi.org/10.1186/1471-2202-15-36
Chan AW, Jiang J, Chen Y et al (2015) Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood. PLoS One 10(5):e0122335
Storey E, Cipolloni PB, Ferrrante RJ et al (1994) Movement disorder following excitotoxin lesions in primates. Neuroreport 5:1259–1261
Hantraye P, Leroy-Willig A, Denys A et al (1992) Magnetic resonance imaging to monitor pathology of caudate-putamen after excitotoxin-induced neuronal loss in the nonhuman primate brain. Exp Neurol 118:18–23
Kanazawa I, Kimura M, Murata M et al (1990) choreic movements in the macaque monkey induced by kainic acid lesions of the striatum combined with l-dopapharmacological, biochemical and physiological studies on neural mechanisms. Brain 113:509–535
Baxa M, Hruska-Plochan M, Juhas S et al (2013) A transgenic minipig model of Huntington’s disease. J Huntingtons Dis 2:47–68
Morton AJ, Howland DS (2013) Large genetic animal models of Huntington’s disease. J Huntingtons Dis 2:3–19
Reid SJ, Patassini S, Handley RR et al (2013) Further molecular characterisation of the OVT73 transgenic sheep model of Huntington’s disease identifies cortical aggregates. J Huntingtons Dis 2:279–295
Jacobsen JC, Bawden CS, Rudiger SR et al (2010) An ovine transgenic Huntington’s disease model. Hum Mol Genet 19:1873–1882
Yang D, Wang CE, Zhao B et al (2010) Expression of Huntington’s disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet 19:3983–3994
Handley RR, Reid SJ, Patassini S et al (2016) Metabolic disruption identified in the Huntington’s disease transgenic sheep model. Sci Rep 6:20681. https://doi.org/10.1038/srep20681
Chan AW, Yang SH (2009) Generation of transgenic monkeys with human inherited genetic disease. Methods 49:78–84
Wang CE, Tydlacka S, Orr AL et al (2008) Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington’s disease. Hum Mol Genet 17:2738–2751
Palfi S, Brouillet E, Jarraya B et al (2007) Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther 15:1444–1451
Aron Badin R, Callander G et al (2013) Characterization of a novel striatal-specific non-human primate model of Huntington’s disease. Movement Disorders. In: 17th International Congress of the Parkinson’s Disease and Movements Disorders, Sydney, Australia, 16–20 June 2013, p. 103, abstract 754
Phillips KA, Bales KL, Capitanio JP et al (2014) Why primate models matter. Am J Primatol 76:801–827
Ventura-Antunes L, Mota B, Herculano-Houzel S (2013) Different scaling of white matter volume, cortical connectivity, and gyrification across rodent and primate brains. Front Neuroanat 7:3. https://doi.org/10.3389/fnana.2013.00003
Insausti R (2013) Comparative neuroanatomical parcellation of the human and nonhuman primate temporal pole. J Comp Neurol 521:4163–4176
Roth G, Dicke U (2005) Evolution of the brain and intelligence. Trends Cogn Sci 9:250–257
Semendeferi K, Lu A, Schenker N, Damasio H (2002) Humans and great apes share a large frontal cortex. Nat Neurosci 5:272–276
Seelke AM, Dooley JC, Krubitzer LA (2012) The emergence of somatotopic maps of the body in S1 in rats: the correspondence between functional and anatomical organization. PLoS One 7(2):e32322
Hantraye P, Palfi S, Mittoux V et al (2000) Replicating Huntington disease’s phenotype in nonhuman primates. In: Emerich DF, Dean RL, Sanberg PR (eds) Central nervous system diseases: innovative animal models from lab to clinic. Humana Press, Totowa, NJ, pp 333–353
Aron Badin R, Hantraye P (2012) Designing primate models to assess the prodromal phase of Huntington’s disease. Rev Neurol 168:802–805
Aron Badin R, Vadori M, Cozzi E, Hantraye P (2015) Translational research for Parkinsons disease: the value of pre-clinical primate models. Eur J Pharmacol 759:118–126
Wolfe JH (2009) Gene therapy in large animal models of human genetic diseases. ILAR J 50:107–111
Haley PJ (2003) Species differences in the structure and function of the immune system. Toxicology 188:49–71
Isacson O, Hantraye P, Maziere M et al (1990) Apomorphine-induced dyskinesias after excitotoxic caudate-putamen lesions and the effects of neural transplantation in non-human primates. Prog Brain Res 82:523–533
Emerich DF, Thanos CG, Goddard M et al (2006) Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis 23:471–480
Isacson O, Riche D, Hantraye P et al (1989) A primate model of Huntington’s disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen. Exp Brain Res 75:213–220
Simmons JT, Pastakia B, Chase TN, Shults CW (1986) Magnetic resonance imaging in Huntington disease. AJNR Am J Neuroradiol 7:25–28
Palfi S, Conde F, Riche D et al (1998) Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 4:963–966
Simmons NE, Helm GA, Cail WS et al (1994) Magnetic resonance imaging of neuronal grafts in the primate. Exp Neurol 125:52–57
Denys A, Leroy-Willig A, Riche D, Hantraye P (1992) MR appearance of neural grafts in a primate model of Huntington disease. Am J Roentgenol 158:215–216
Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol 81:294–330
Borrell-Pages M, Canals JM, Cordelieres FP et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116:1410–1424
Emerich DF, Winn SR, Harper J et al (1994) Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol 349:148–164
Kordower JH, Winn SR, Liu YT et al (1994) The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci U S A 91:10898–10902
Emerich DF, Winn SR, Hantraye PM et al (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s disease. Nature 386:395–399
Mittoux V, Joseph JM, Conde F et al (2000) Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington’s disease. Hum Gene Ther 11:1177–1187
Bachoud-Levi AC, Deglon N, Nguyen JP et al (2000) Neuroprotective gene therapy for Huntington’s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11:1723–1729
Bloch J, Bachoud-Levi AC, Deglon N et al (2004) Neuroprotective gene therapy for Huntington’s disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968–975
Emborg ME, Hurley SA, Joers V et al (2014) Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery. Stereotact Funct Neurosurg 92:182–194
Moirano J, Emborg ME (2006) Chapter 9 – Nonhuman primate models for testing gene therapy for neurodegenerative disorders A2 – Kaplitt, Michael G. In: During MJ (ed) Gene therapy of the central nervous system. Academic Press, Amsterdam, pp 109–119
Ramaswamy S, Kordower JH (2012) Gene therapy for Huntington’s disease. Neurobiol Dis 48:243–254
Ruozi B, Belletti D, Bondioli L et al (2012) Neurotrophic factors and neurodegenerative diseases: a delivery issue. Int Rev Neurobiol 102:207–247
Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington’s disease and spinocerebellar ataxia. Hum Mol Genet 25:R53–R64
Godinho BM, Malhotra M, O’Driscoll CM, Cryan JF (2015) Delivering a disease-modifying treatment for Huntington’s disease. Drug Discov Today 20:50–64
Pfister EL, Kennington L, Straubhaar J et al (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s disease patients. Curr Biol 19:774–778
Ruiz M, Deglon N (2012) Viral-mediated overexpression of mutant huntingtin to model HD in various species. Neurobiol Dis 48:202–211
Hadaczek P, Eberling JL, Pivirotto P et al (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18:1458–1461
Drouet V, Perrin V, Hassig R et al (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276–285
Lombardi MS, Jaspers L, Spronkmans C et al (2009) A majority of Huntington’s disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 217:312–319
Ostergaard ME, Southwell AL, Kordasiewicz H et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41:9634–9650
McBride JL, Pitzer MR, Boudreau R et al (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther 19:2152–2162
Grondin R, Kaytor MD, Ai Y, Nelson PT et al (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135:1197–1209
Stiles DK, Zhang Z, Ge P et al (2012) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233:463–471
Grondin R, Ge P, Chen Q et al (2015) Onset time and durability of huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA. Mol Ther Nucleic Acids 4:e245
Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74:1031–1044
Downs ME, Buch A, Sierra C et al (2015) Correction: Long-term safety of repeated blood-brain barrier opening via focused ultrasound with microbubbles in non-human primates performing a cognitive task. PLoS One 10:e0130860
Kumar A, Kumar Singh S, Kumar V et al (2015) Huntington’s disease: an update of therapeutic strategies. Gene 556:91–97
Ripaud L, Chumakova V, Antonin M et al (2014) Overexpression of Q-rich prion-like proteins suppresses polyQ cytotoxicity and alters the polyQ interactome. Proc Natl Acad Sci U S A 111:18219–18224
Faideau M, Kim J, Cormier K et al (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects. Hum Mol Genet 19:3053–3067
Crotti A, Glass CK (2015) The choreography of neuroinflammation in Huntington’s disease. Trends Immunol 36:364–373
Benraiss A, Wang S, Herrlinger S et al (2016) Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun 7:11758
Escartin C, Bonvento G (2008) Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol 38:231–241
Acknowledgments
The authors acknowledge that the genetic model of HD in primates was jointly developed with Dr. Nicole Déglon and Dr. Marta Ruiz.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Aron Badin, R. (2018). Nonhuman Primate Models of Huntington’s Disease and Their Application in Translational Research. In: Precious, S., Rosser, A., Dunnett, S. (eds) Huntington’s Disease. Methods in Molecular Biology, vol 1780. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7825-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7825-0_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7824-3
Online ISBN: 978-1-4939-7825-0
eBook Packages: Springer Protocols